Essential hypertension is typically diagnosed by screening of an asymptomatic individual.
Treatment of uncontrolled hypertension reduces the risks of mortality and of cardiac, vascular, renal, and cerebrovascular complications.
Lifestyle changes are recommended for all patients: weight loss, exercise, decreased sodium intake, Dietary Approaches to Stop Hypertension (DASH) diet, and moderation of alcohol consumption.
Choice of drug therapy is often driven by considerations related to comorbid disease, but achievement of blood pressure goal may be accomplished with a variety of therapeutic agent(s).
Essential hypertension is defined as blood pressure (BP) ≥140/90 mmHg, with no secondary cause identified. The main goal of treatment is to decrease the risk of mortality and of cardiovascular and renal morbidity.
The Eighth Joint National Committee (JNC 8) guideline recommends starting pharmacologic treatment in patients with chronic kidney disease and diabetes if BP ≥140/90 mmHg. In the general population aged ≥60 years, treatment to lower blood pressure should begin when BP ≥150/90 mmHg. The latter recommendation was not agreed upon by all panel members because of the risk of cardiovascular events associated with BP ≥140/90 mmHg.
In the 2018 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines, hypertension is defined as office systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, which is equivalent to a 24-hour ambulatory blood pressure measurement average of ≥130/80 mmHg, or a home blood pressure measurement average of ≥135/85 mmHg.
Blood pressure goals and recommendations continue to evolve in line with new evidence.
The 2017 American College of Cardiology/American Heart Association guideline defines hypertension as any systolic blood pressure measurement of ≥130 mmHg or any diastolic BP measurement of ≥80 mmHg. This definition differs from the JNC 8, ESC, and ESH guidelines.
The SPRINT trial (Systolic Blood Pressure Intervention Trial) found that a lower systolic target of 120 mmHg (as measured by automated office blood pressure) reduced cardiovascular complications and deaths in people aged over 50 years with high blood pressure and at least one additional risk factor for heart disease. Patients with diabetes or stroke were excluded from the trial.
History and exam
Regional Hypertension Co-Lead
JB declares that he has no competing interests.
Dr Jeffrey Brettler would like to gratefully acknowledge Dr Joel Handler, Dr Jonathan N. Bella, Dr Moustapha Atoui, Dr Liran Blum, and Dr Michael A. Spinelli, previous contributors to this topic.
JH, JNB, MA, LB, and MAS declare that they have no competing interests.
Clinical Senior Lecturer in Clinical Pharmacology and Honorary Consultant Physician
University of Dundee
IM is an elected member of the British Hypertension Society Executive Committee.
Department of Cardiology
University of Texas MD Anderson Cancer Center
SWY declares that he has no competing interests.
Director Barts Blood Pressure Centre of Excellence
NHS Reader in Cardiovascular Medicine
Department of Clinical Pharmacology
William Harvey Heart Centre
ML is a consultant for ROX Medical. ML receives honorarium from Cardiosonic, St. Jude Medical, and institutional grant/research support from Medtronic.
Use of this content is subject to our disclaimer